Medexus Pharmaceuticals Inc.

TSX:MDP Stock Report

Market Cap: CA$69.5m

Medexus Pharmaceuticals Management

Management criteria checks 2/4

Medexus Pharmaceuticals' CEO is Ken d'Entremont, appointed in Dec 2018, has a tenure of 6.17 years. total yearly compensation is $1.11M, comprised of 46.8% salary and 53.2% bonuses, including company stock and options. directly owns 6.03% of the company’s shares, worth CA$4.19M. The average tenure of the management team and the board of directors is 4.5 years and 6.2 years respectively.

Key information

Ken d'Entremont

Chief executive officer

US$1.1m

Total compensation

CEO salary percentage46.8%
CEO tenure6yrs
CEO ownership6.0%
Management average tenure4.5yrs
Board average tenure6.2yrs

Recent management updates

Recent updates

After Leaping 31% Medexus Pharmaceuticals Inc. (TSE:MDP) Shares Are Not Flying Under The Radar

Dec 05
After Leaping 31% Medexus Pharmaceuticals Inc. (TSE:MDP) Shares Are Not Flying Under The Radar

Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?

Nov 05
Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?

There May Be Reason For Hope In Medexus Pharmaceuticals' (TSE:MDP) Disappointing Earnings

Aug 19
There May Be Reason For Hope In Medexus Pharmaceuticals' (TSE:MDP) Disappointing Earnings

Medexus Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Aug 10
Medexus Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Medexus Pharmaceuticals Inc. (TSE:MDP) Shares Fly 29% But Investors Aren't Buying For Growth

Jul 31
Medexus Pharmaceuticals Inc. (TSE:MDP) Shares Fly 29% But Investors Aren't Buying For Growth

The Market Doesn't Like What It Sees From Medexus Pharmaceuticals Inc.'s (TSE:MDP) Revenues Yet

Jun 15
The Market Doesn't Like What It Sees From Medexus Pharmaceuticals Inc.'s (TSE:MDP) Revenues Yet

Here's Why Medexus Pharmaceuticals (TSE:MDP) Has A Meaningful Debt Burden

Apr 25
Here's Why Medexus Pharmaceuticals (TSE:MDP) Has A Meaningful Debt Burden

Revenues Working Against Medexus Pharmaceuticals Inc.'s (TSE:MDP) Share Price Following 26% Dive

Mar 03
Revenues Working Against Medexus Pharmaceuticals Inc.'s (TSE:MDP) Share Price Following 26% Dive

Medexus Pharmaceuticals Inc.'s (TSE:MDP) Shares Leap 89% Yet They're Still Not Telling The Full Story

Jan 06
Medexus Pharmaceuticals Inc.'s (TSE:MDP) Shares Leap 89% Yet They're Still Not Telling The Full Story

Here's Why Medexus Pharmaceuticals (TSE:MDP) Has Caught The Eye Of Investors

Oct 11
Here's Why Medexus Pharmaceuticals (TSE:MDP) Has Caught The Eye Of Investors

Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?

Sep 11
Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?

Medexus Pharmaceuticals (TSE:MDP) Use Of Debt Could Be Considered Risky

Jan 19
Medexus Pharmaceuticals (TSE:MDP) Use Of Debt Could Be Considered Risky

Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?

Sep 22
Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?

Is Medexus Pharmaceuticals (TSE:MDP) Weighed On By Its Debt Load?

Dec 16
Is Medexus Pharmaceuticals (TSE:MDP) Weighed On By Its Debt Load?

CEO Compensation Analysis

How has Ken d'Entremont's remuneration changed compared to Medexus Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

US$2m

Jun 30 2024n/an/a

US$1m

Mar 31 2024US$1mUS$517k

-US$214k

Dec 31 2023n/an/a

US$6m

Sep 30 2023n/an/a

US$5m

Jun 30 2023n/an/a

US$3m

Mar 31 2023US$882kUS$400k

US$1m

Dec 31 2022n/an/a

-US$11m

Sep 30 2022n/an/a

-US$11m

Jun 30 2022n/an/a

US$2m

Mar 31 2022US$592kUS$400k

-US$3m

Dec 31 2021n/an/a

-US$8m

Sep 30 2021n/an/a

-US$20m

Jun 30 2021n/an/a

-US$31m

Mar 31 2021US$688kUS$328k

-US$28m

Dec 31 2020n/an/a

-US$19m

Sep 30 2020n/an/a

-US$9m

Jun 30 2020n/an/a

-US$7m

Mar 31 2020US$385kUS$300k

-US$5m

Dec 31 2019n/an/a

-US$4m

Sep 30 2019n/an/a

-US$3m

Jun 30 2019n/an/a

-US$6m

Mar 31 2019US$2mUS$144k

-US$5m

Compensation vs Market: Ken's total compensation ($USD1.11M) is above average for companies of similar size in the Canadian market ($USD164.16K).

Compensation vs Earnings: Ken's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.

CEO

Ken d'Entremont

6yrs

Tenure

US$1,106,271

Compensation

Mr. Kenneth d'Entremont, also known as Ken, has been Chief Executive Officer at Medexus Pharmaceuticals Inc. (formerly Pediapharm Inc.) since December 17,2018 and served as its Chief Operating Officer sinc...

Leadership Team

NamePositionTenureCompensationOwnership
Kenneth d'Entremont
CEO & Director6yrsUS$1.11m6.03%
CA$ 4.2m
Richard Labelle
Chief Operating Officerno dataUS$374.12k0.11%
CA$ 76.2k
Ian Wildgoose Brown
General Counsel & Corporate Secretary3.1yrsUS$446.08k0.084%
CA$ 58.2k
Brendon Buschman
Chief Financial Officerless than a yearno datano data
Tina Byers
Executive of Investor Relationsno datano datano data
Bill Poncy
Senior Vice President of Commercial Operations - United States6.2yrsUS$439.69kno data
Brian Peters
Vice President of Sales & Marketing - United Statesno dataUS$281.91kno data

4.5yrs

Average Tenure

Experienced Management: MDP's management team is considered experienced (4.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Kenneth d'Entremont
CEO & Director6.2yrsUS$1.11m6.03%
CA$ 4.2m
Michael Mueller
Independent Chairman10.6yrsUS$94.71k0.39%
CA$ 273.7k
Benoit Gravel
Independent Director7.3yrsUS$83.38k0.26%
CA$ 179.2k
Stephen Nelson
Independent Director6.2yrsUS$73.94k2.25%
CA$ 1.6m
Nancy Phelan
Independent Director1.3yrsUS$39.27k0.045%
CA$ 31.5k
Harmony Garges
Independent Director1.8yrsUS$62.92k0.099%
CA$ 68.8k
Menassie Taddese
Independent Director1.8yrsUS$66.90k0.099%
CA$ 68.8k

6.2yrs

Average Tenure

55yo

Average Age

Experienced Board: MDP's board of directors are considered experienced (6.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 09:42
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Medexus Pharmaceuticals Inc. is covered by 11 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David MartinBloom Burton & Co.
Tania Armstrong-WhitworthCanaccord Genuity
Tania Armstrong-WhitworthCormark Securities Inc.